Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.58 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.58 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.58 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854946 | 1.00 | HPGD (0.59) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL11298351 | 0.83 | TNKS (0.53) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL12867892 | 0.81 | ALOX15 (0.57) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL11291776 | 0.77 | TNKS (0.47) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL40354 | 0.77 | EPHX2 (0.50) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL7372279 | 0.77 | EPHX2 (0.61) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL21623585 | 0.77 | MAPT (0.55) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL28490130 | 0.76 | TNKS (0.50) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL29689973 | 0.75 | KDM4E (1.00) | HPGDKDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL29702211 | 0.75 | NPC1 (0.61) | HPGDKDM4EALDH1A1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079805-A | Preparation method of trifluoromethyl chromone compound | 浙江瑞博制药有限公司 | 2020-12-15 | — | — | CN | claimed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-111574510-B | Pyrimidine as herbicide Oxyphenyl derivatives | FMC 公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-3094631-B2 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES | FMC CORP (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024192309-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-11447476-B2 | Pyrimidinyloxy benzene derivatives as herbicides | FMC CORPORATION (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022165432-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-114560837-A | Chromone compound and preparation method and application thereof | 五邑大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-112079805-A | Preparation method of trifluoromethyl chromone compound | 浙江瑞博制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112079805-A | Preparation method of trifluoromethyl chromone compound | 浙江瑞博制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3094631-A1 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES | E. I. du Pont de Nemours and Company (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160333000-A1 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES | FMC CORPORATION | 2016-11-17 | — | — | US | disclosed |
| CN-105916849-A | Pyrimidinyloxybenzene derivatives as herbicides | 纳幕尔杜邦公司 | 2016-08-31 | — | — | CN | disclosed |
| WO-2015108779-A1 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333000-A1 | PYRIMIDINYLOXY BENZENE DERIVATIVES AS HERBICIDES | DDT, NQO2, CBR3 | HPGD 734/4885KDM4E 2150/4885ALDH1A1 514/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | HPGD 2938/4885KDM4E 996/4885ALDH1A1 3401/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | HPGD 2938/4885KDM4E 996/4885ALDH1A1 3401/4885 |
| US-11447476-B2 | Pyrimidinyloxy benzene derivatives as herbicides | DDT, NQO2, CBR3 | HPGD 734/4885KDM4E 2150/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.